New York City data highlight the benefits of early administration of nirsevimab to safeguard infants from respiratory ...

RSV cases, hospitalisations and ICU admissions notified in 12 weeks to mid-November were between six and seven times lower ...

RSV season is beginning, but for the first time, parents can access an effective treatment to protect their infants from this common but dangerous virus.

The first study, published yesterday in Clinical Infectious Diseases, includes results of a phase 3 clinical trial (MELODY), ...

Your child may have RSV. RSV or respiratory syncytial virus is a common seasonal infection usually peaking in January. This condition is most noticeable in our young patients. Their airways are ...

Seasonal maternal respiratory syncytial virus (RSV) vaccination and nirsevimab for infants demonstrate cost-effectiveness.

Use of nirsevimab was associated with an approximately 80% reduction in illness due to respiratory syncytial virus (RSV) ...

A recently approved immunization drug is helping to limit the severity of a respiratory disease that afflicts young children ...

The following is a summary of “Parent Perspectives on Nirsevimab for Their Newborn,” published in the November 2024 issue of ...